Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex

TL;DR: This work investigates whether ERK pathway signaling in response to EGF stimulation, leads to changes in the production of long non-coding RNAs, and identifies several different classes of EGF pathway-regulated lncRNAs.

TL;DR: The bases of DNA recognition of Transcription activator-like effectors, including methylated cytosine recognition, and the applications of TALEs for the study of methylated DNA are described.

TL;DR: The evolutionary history of CRISPR/Cas9 system, the working principle and modification process, and its application in animal genome modification are summarized to provide innovative perspectives on improving animal traits and establishing animal models of human diseases.

TL;DR: This model provides a resource of optimized Cas13 guide RNAs to target all protein-coding transcripts in the human genome, enabling transcriptome-wide forward genetic screens and confirms the model’s generalizability across a large number of endogenous target mRNAs and shows that Cas13 can be used in forward genetic pooled CRISPR-screens to identify essential genes.

TL;DR: It is shown that accurate gene-level abundance estimates are best obtained with large numbers of short single-end reads, and estimates of the relative frequencies of isoforms within single genes may be improved through the use of paired- end reads, depending on the number of possible splice forms for each gene.

TL;DR: This study reveals a family of endonucleases that use dual-RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA-programmable genome editing.

TL;DR: The results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents and the generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of ‘personalized’ therapeutic regimens.

TL;DR: A new version of the database, MSigDB 3.0, is reported, with over 6700 gene sets, a complete revision of the collection of canonical pathways and experimental signatures from publications, enhanced annotations and upgrades to the web site.